PT  - JOURNAL ARTICLE
AU  - Fokam, Joseph
AU  - Mpouel Bala Yanga, Marie Laure
AU  - Santoro, Maria-Mercedes
AU  - Takou, Désiré
AU  - Tala, Valère
AU  - Beloumou, Grace
AU  - Ngoufack, Ezechiel Semengue
AU  - Chenwi, Collins
AU  - Togna Pabo, Willy Leroy
AU  - Njume, Debimeh
AU  - Teto, Georges
AU  - Dambaya, Béatrice
AU  - Djupsa, Sandrine
AU  - Sosso, Samuel
AU  - Ateba, Francis
AU  - Kamta, Cedric
AU  - Bala, Lionel
AU  - Njom Nlend, Anne Esther
AU  - Ndombo, Paul Koki
AU  - Colizzi, Vittorio
AU  - Perno, Carlo Frederico
AU  - Ndjolo, Alexis
TI  - PA-402 Predictors of archived HIV-1 drug resistance mutations in cellular reservoirs of virally suppressed adolescents: the EDCTP READY-study TMA2025-CDF1027
AID  - 10.1136/bmjgh-2023-EDC.188
DP  - 2023 Dec 01
TA  - BMJ Global Health
PG  - A77--A77
VI  - 8
IP  - Suppl 10
4099  - http://gh.bmj.com/content/8/Suppl_10/A77.1.short
4100  - http://gh.bmj.com/content/8/Suppl_10/A77.1.full
SO  - BMJ Global Health2023 Dec 01; 8
AB  - Background Even though 92% of people receiving antiretroviral treatment (ART) have achieved viral suppression (VS) globally, adolescents with perinatal HIV-infection (APHI) have challenges in sustaining VS, probably due to HIV-1 archived drug resistance mutations (ADRMs). Our objective was to investigate on ADRMs among APHI on VS in Cameroon.Methods An analytical study was conducted in 2021 among 38 consenting APHI on VS at the Chantal BIYA International Reference Centre (CIRCB) in Yaoundé-Cameroon. Proviral-HIV-1 DNA was extracted from buffy coat, DNA extracts were amplified, purified and sequenced by capillary electrophoresis. Generated proviral sequences were used to analyse ADRMs on HIVdb.v9.0. Molecular phylogeny was performed with MEGA v10x and data were analysed with a significance threshold of 5%.Results A total of 30 samples were successfully amplified, of which 28 sequences were obtained and one sequence was excluded due to APOBEC3G mutations. Sex ratio M/F was 3/4; median age was 14 years [IQR: 13–16.5]. Regarding ART, twelve (42.9%) were on first line, and the most common regimens were TDF+3TC+EFV and TDF+3TC+ATV/r; and 64.3% (18/28) were fully adherent. Regarding ART response, 92.9% were at WHO clinical stages 1/2; median CD4 was 642 [IQR: 421–769] cells/mm3; 32.1% (09/28) had undetectable viraemia. The prevalence of ADRMs was 59.2% (16/27), of which main DRMs by class were M184MV/I (25%), T215Y/IL/FS (15.9%) for nucleoside reverse transcriptase inhibitors (NRTIs); K103K/N (25.7%), A98A/G (14.3%) for non-NRTIs; I54V and V82VA (3.7% each) for PI/r. Second line of ART were associated with ADRMs (p=0.001). ADRMs were found in detectable (66.6% i.e. 12/18) versus undetectable viraemia (44.4% i.e. 04/09), p=0.58. Seven HIV-1clades were found, with CRF02_AG being prevalent (67.8%). Conclusion Despite VS, APHI harbour ADRMs, which underscore high risks of subsequent ART failure, even with undetectable viraemia. Limiting emerging ADRMs suggest targeting APHI on second-line ART, after previous exposure to NRTI-containing regimens.